The True Mission of InnovaCare Health

Every healthcare company says that their mission is helping their patients. Meanwhile, most people suffer from lack of quality medical care. Whose fault is that? The selfish answer, which is what most famous healthcare companies respond with, is that the average person has trouble affording healthcare.While that is true, people’s lack of money isn’t the sole reason for that problem. Part of that is also because medical care is expensive; not everyone can afford even the barest healthcare essentials. The major problem is today’s healthcare environment is just too complex. But now the question becomes: who’s responsible for resolving the healthcare issues?Well, that’s one of the most debated questions in the industry. Sadly, while everyone’s debating, there are still millions of people suffering from lack of quality medical care. That’s why it’s so important to have companies like InnovaCare Health. InnovaCare’s made redefining the current healthcare management environment their number one mission.

InnovaCare believes in relying on patient-provider relationships to create a better healthcare system. By focusing more on patients, InnovaCare is able to ensure every outcome is the healthiest and enhances their patients’ lives. Everything InnovaCare does is for the benefit of their patients.The true focus of InnovaCare starts at the top with their leadership. Their greatest leadership asset is Dr. Richard Shinto. For more than 20 years, Dr. Shinto has worked in the managed care industry. His experience ranges from clinical to operational healthcare. His accomplishments earned him many promotions, including being named President and CEO.

One thing that sums up Dr. Shinto’s effectiveness as a leader is becoming CEO of InnovaCare’s Health Plans subsidiary. Only a few years after joining InnovaCare, he led the company to the number one spot as Puerto Rico’s most popular managed care provider.Another great member of InnovaCare’s leadership is Penelope Kokkinides. Currently serving as Chief Administrative Officer, Penelope Kokkinides brings her own contributions to the table. She also has a 20-plus-year career in the managed care industry. She specializes in government programs and developing new health models.While working at AmeriChoice as Corporate VP for Care Management and Disease Management, she helped the company with their new health model. She’s an expert at managing strategic direction and health care operations. Much of what she does goes toward improving efficiencies.

Amicus Therapeutics is Changing Lives for People Who Have Diseases and Disorders that are Uncommon

Amicus is the American biopharmaceutical company that is located in Cranbury, New Jersey. Amicus Therapeutics went public back in the year 2007 where they operated under the NASDAQ symbol of FOLD. This business was created by many venture capital firms which included the firm Radius Ventures(Yahoo Finance). It also worked alongside of New Enterprise Associates.

The therapeutic focus for the business is surrounding orphan and rare diseases. It works to create a plan on different therapy options for various diseases and in 2014, the business was said to have the largest portfolio for small molecules within the pharmacological chaperones within the industry of pharmaceuticals.

There are a number of diseases out there that leaves patients without hope that they can be cured or treated. A specific example is of Fabry Disease. This disease is a genetic disorder and to help people overcome the disease, the latest product of Amicus Therapeutics is Migalastat. By creating a number of enzyme replacement therapies, patients who suffer from this disease are able to see a difference in their lives.

The goal of Amicus Therapeutics is to help patients who are suffering from a disease to live longer and healthier lives by allowing therapies to work to alleviate the symptoms of various diseases. They are very passionate and the work they are doing and are always thinking of different things to do to help patients. As long as they continue to push the idea of each therapy and to take a number of risks that will push for different advances to be made, more patients are able to be helped when they suffer from a genetic disorder or disease.

The goal of the company is to think outside of the box and to keep asking the questions that are the hardest to answer. The business knows that in order to make a difference, they have to know and understand the mistakes that have been made. Once you understand a mistake and know how to avoid it, you start to learn how to avoid it and bypass it the next time. It encourages more hope and promise which is what patients need when they suffer from a disease or disorder.

Check out Amicus Therapeutics on Twitter and Facebook

Dr. Scott Rocklage’s Contribution in Healthcare Management

Scott Rocklage, Ph.D.; a Managing Partner of 5AM Ventures, has an experience of over 30 years in healthcare management with strategic leadership commitment that resulted in the approval of three New Drug Applications in the United States. This has enabled several drug candidates to enter into clinical trials. Dr. Rocklage joined 5AM Ventures as a Venture Partner in 2003 and later became a Managing Partner in 2004.

Dr. Rocklage has served as the Chief Executive Officer (CEO) and Chairman of Cubist Pharmaceuticals; a biopharmaceutical firm that focuses on the development, research, and commercialization of products that address vital needs in the care environment and as CEO and President of Nycomed Salutar; a biotechnology company. He also held various research and development (R&D) positions at Catalytica and Salutar. Currently, Dr. Rocklage serves as the Board Chairman of Kinestral, Rennovia, and Cidara. He also serves on the Boards of Pulmatrix and Epirus.

Formerly the Executive Chairman of Miikana that was acquired by EntreMed, Semprus; acquired by Teleflex, and Ilypsa; acquired by Amgen, Dr. Rocklage earned his Bachelor of Science degree in Chemistry from the University of California, Berkley. He holds a Ph.D. in Chemistry from the Institute of Technology Massachusetts where he researched from the Richard Schrock Laboratory; a 2005 Nobel Winning Chemistry laboratory. Dr. Rocklage is the co-inventor or an inventor on more than 30 patents in the United States and over 100 publications that have been peer-reviewed. Based in Boston, Dr. Rocklage has an extensive scientific background, leadership track record, and healthcare management experience. Click here to know more.

5AM Ventures is a leading venture capital company focused on establishing next-generation life science firms that are capable of delivering exceptional returns to their investors. They support enterprises that are aiming at providing solutions to pressing health care concerns through cutting-edge successes in science and medicine. Moreover, their pioneering companies spearhead the best approaches to diagnose, treat, and prevent various medical conditions.

5AM Venture professionals have substantial medical, scientific, operational, finance, and legal expertise. Their complementary backgrounds also offer them a unique way of finding and shaping life science firms. The venture is always directly involved in setting solid strategy, business development, fundraising, and management recruitment. Apart from taking on short-term operational roles, 5AM professionals contribute as board members in various healthcare organizations.